Table of Contents
ISRN AIDS
Volume 2012, Article ID 960178, 6 pages
http://dx.doi.org/10.5402/2012/960178
Research Article

Prevalence of HIV-Associated Metabolic Abnormalities among Patients Taking First-Line Antiretroviral Therapy in Uganda

1School of Medicine, Makerere University College of Health Sciences, P.O. Box 7072, Kampala, Uganda
2Research Department, Infectious Diseases Institute, Makerere University College of Health Sciences, P.O. Box 22418, Kampala, Uganda
3Institute of Tropical Medicine, Nationalestraat 155, University of Antwerp, Antwerp, Belgium
4Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Received 18 May 2012; Accepted 25 June 2012

Academic Editors: O. Andersen, L. Belec, and L. Gray

Copyright © 2012 Bernard Omech et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, “Towards universal access: scaling up priority HIV/AIDS interventions in the health sector,” in Progress Report, World Health Organization, Geneva, 2008. View at Google Scholar
  2. A. R. Zolopa, J. Andersen, L. Komarow et al., “Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial,” PLoS ONE, vol. 4, no. 5, Article ID e5575, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Womack, “HIV-related lipodystrophy in Africa and Asia,” AIDS Reader, vol. 19, no. 4, pp. 148–152, 2009. View at Google Scholar · View at Scopus
  4. S. Mercier, N. F. N. Gueye, A. Cournil et al., “Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in senegal: a case-control study,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 2, pp. 224–230, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Mutimura, A. Stewart, P. Rheeder, and N. J. Crowther, “Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 46, no. 4, pp. 451–455, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. WHO, Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach, 2006.
  7. C. Grunfeld, M. Pang, W. Doerrler, J. K. Shigenaga, P. Jensen, and K. R. Feingold, “Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome,” The Journal of Clinical Endocrinology and Metabolism, vol. 74, no. 5, pp. 1045–1052, 1992. View at Publisher · View at Google Scholar · View at Scopus
  8. K. R. Feingold, R. M. Krauss, M. Pang, W. Doerrler, P. Jensen, and C. Grunfeld, “The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B,” The Journal of Clinical Endocrinology and Metabolism, vol. 76, no. 6, pp. 1423–1427, 1993. View at Publisher · View at Google Scholar · View at Scopus
  9. H. C. F. Côté, Z. L. Brumme, K. J. P. Craib et al., “Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients,” The New England Journal of Medicine, vol. 346, no. 11, pp. 811–820, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. E. M. Manuthu, M. D. Joshi, G. N. Lule, and E. Karari, “Prevalence of dyslipidemia and dysglycaemia in HIV infected patients,” East African Medical Journal, vol. 85, no. 1, pp. 10–17, 2008. View at Google Scholar · View at Scopus
  11. WHO, Diabetes Mellitus: Report of a WHO Study Group, 1985.
  12. S. M. Grundy, D. Becker, L. T. Clark et al., “Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III),” Circulation, vol. 106, no. 25, pp. 3143–3421, 2002. View at Google Scholar · View at Scopus
  13. G. S. Bimenya, W. Byarugaba, S. Kalungi et al., “Initial attempt to establish population reference values for blood glucose and lipids in Makerere University undergraduate students,” African Health Sciences, vol. 6, no. 4, pp. 247–253, 2006. View at Google Scholar · View at Scopus
  14. K. Buchacz, P. J. Weidle, D. Moore et al., “Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the Home-Based AIDS Care Program in Rural Uganda,” Journal of Acquired Immune Deficiency Syndromes, vol. 47, no. 3, pp. 304–311, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Castelnuovo, A. Kiragga, M. R. Kamya, and Y. Manabe, “Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda,” Journal of Acquired Immune Deficiency Syndromes, vol. 56, no. 1, pp. 59–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. D. M. Zannou, L. Denoeud, K. Lacombe et al., “Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin,” Antiviral Therapy, vol. 14, no. 3, pp. 371–380, 2009. View at Google Scholar · View at Scopus
  17. F. R. Sattler, D. Qian, S. Louie et al., “Elevated blood pressure in subjects with lipodystrophy,” AIDS, vol. 15, no. 15, pp. 2001–2010, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Van Leth, P. Phanuphak, E. Stroes et al., “Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1,” PLoS Medicine, vol. 1, no. 1, article e19, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. K. A. Lichtenstein, D. J. Ward, A. C. Moorman et al., “Clinical assessment of HIV-associated lipodystrophy in an ambulatory population,” AIDS, vol. 15, no. 11, pp. 1389–1398, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Friis-Møller, R. Weber, P. Reiss et al., “Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study,” AIDS, vol. 17, no. 8, pp. 1179–1193, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Mutimura, N. J. Crowther, T. W. Cade, K. E. Yarasheski, and A. Stewart, “Exercise training reduces central adiposity and improves metabolic indices in HAART-treated HIV-positive subjects in Rwanda: a randomized controlled trial,” AIDS Research and Human Retroviruses, vol. 24, no. 1, pp. 15–23, 2008. View at Publisher · View at Google Scholar · View at Scopus